Nyxoah shares rose 7% premarket after CMS finalised CY2026 rules increasing Hospital Outpatient Department reimbursement for its Genio hypoglossal nerve stimulation implants to about $45,000. The company expects stronger adoption, higher procedural throughput, and expanded access across Medicare-heavy centers, with new opportunities for ambulatory surgery centers as well.